ArticleIJU case reports2026
Multiple Bone Metastases From Non-Muscle Invasive Bladder Cancer Responding to Combination Therapy With Enfortumab Vedotin and Pembrolizumab: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We report a case in which combination therapy with enfortumab vedotin (EV) and pembrolizumab proved effective in treating non-muscle-invasive bladder cancer (NMIBC) accompanied by multiple bone metastases. Case Presentation: A 61-year-old man with NMIBC underwent eight transurethral resections of bladder tumor (TURBTs) at another hospital over 4 years. During the eighth TURBT, carcinoma in situ was detected, and the patient was treated with intravesical Bacillus Calmette-Guérin (BCG) therapy. A computed tomography scan performed at our hospital 1.5 years after BCG therapy revealed multiple osteosclerotic lesions. Cystoscopy and bladder magnetic resonance imaging revealed no obvious tumorous lesions. An incisional biopsy of the sternum confirmed the diagnosis of multiple bone metastases originating from NMIBC. The patient was started on combination therapy with EV and pembrolizumab. After 5 months, bone scintigraphy revealed decreased accumulation. Conclusion: Combination therapy with EV and pembrolizumab was also effective in treating NMIBC with multiple bone metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.